Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of recombinant GLP-1 receptor agonist injection versus dulaglutide in type 2 diabetes mellitus
CTR20230029Phase 3Completed
- Sponsor
- Lepu Medical
- Start
- May 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Lepu Medical. Started May 2023; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20230029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230029.